157 related articles for article (PubMed ID: 38421234)
1. Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing.
Russell C; Campion M; Grove ME; Matsuda K; Klein TE; Ashley E; Naik H; Wheeler MT; Scott SA
Clin Transl Sci; 2024 Mar; 17(3):e13737. PubMed ID: 38421234
[TBL] [Abstract][Full Text] [Related]
2. Prioritizing pharmacogenomics implementation initiates: a survey of healthcare professionals.
Ho TT; Gift M; Alexander E
Per Med; 2022 Jan; 19(1):15-23. PubMed ID: 34881640
[TBL] [Abstract][Full Text] [Related]
3. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study.
Borden BA; Galecki P; Wellmann R; Danahey K; Lee SM; Patrick-Miller L; Sorrentino MJ; Nanda R; Koyner JL; Polonsky TS; Stadler WM; Mulcahy C; Kavitt RT; Ratain MJ; Meltzer DO; O'Donnell PH
Pharmacogenet Genomics; 2019 Feb; 29(2):31-38. PubMed ID: 30531377
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic education among genetic counseling training programs in North America.
Loudon E; Scott SA; Rigobello R; Scott ER; Zinberg R; Naik H
J Genet Couns; 2021 Oct; 30(5):1500-1508. PubMed ID: 33882174
[TBL] [Abstract][Full Text] [Related]
5. Current state assessment survey of challenges of pharmacogenomics within oncology pharmacy practice.
Przybylski DJ; Dow-Hillgartner EN; Reed MP; Fallon MJ
J Oncol Pharm Pract; 2020 Sep; 26(6):1374-1381. PubMed ID: 31937189
[TBL] [Abstract][Full Text] [Related]
6. Investigation of community pharmacists' knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice.
Ramadan A; Jarab AS; Al Meslamani AZ
Hum Genomics; 2024 Jan; 18(1):8. PubMed ID: 38291455
[TBL] [Abstract][Full Text] [Related]
7. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
8. Attitudes about pharmacogenomic testing vary by healthcare specialty.
Preys CL; Blout Zawatsky CL; Massmann A; Heukelom JV; Green RC; Hajek C; Hickingbotham MR; Zoltick ES; Schultz A; Christensen KD
Pharmacogenomics; 2023 Jul; 24(10):539-549. PubMed ID: 37458095
[No Abstract] [Full Text] [Related]
9. Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.
Liko I; Lee YM; Stutzman DL; Blackmer AB; Deininger KM; Reynolds AM; Aquilante CL
Pharmacogenomics; 2021 Apr; 22(5):263-274. PubMed ID: 33657875
[No Abstract] [Full Text] [Related]
10. Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives.
Bhatt M; Peshkin BN; Kazi S; Schwartz MD; Ashai N; Swain SM; Smith DM
Pharmacogenomics; 2023 Nov; 24(16):859-870. PubMed ID: 37942634
[No Abstract] [Full Text] [Related]
11. Attitudes on pharmacogenomic results as secondary findings among medical geneticists.
Bartos MN; Scott SA; Jabs EW; Naik H
Pharmacogenet Genomics; 2022 Oct; 32(8):273-280. PubMed ID: 35916546
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals.
Pearce A; Terrill B; Alffenaar JW; Patanwala AE; Kummerfeld S; Day R; Young MA; Stocker SL
Intern Med J; 2022 Jul; 52(7):1135-1143. PubMed ID: 35191159
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties.
Johansen Taber KA; Dickinson BD
Pharmgenomics Pers Med; 2014; 7():145-62. PubMed ID: 25045280
[TBL] [Abstract][Full Text] [Related]
14. Opinion, experience and educational preferences concerning pharmacogenomics: an exploratory study of Quebec pharmacists.
Meloche M; Kwon HJ; Letarte N; Bussières JF; Vadnais B; Hurlimann T; Lavoie A; Beauchesne MF; de Denus S
Pharmacogenomics; 2020 Mar; 21(4):235-245. PubMed ID: 32077363
[No Abstract] [Full Text] [Related]
15. Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists.
Gammal RS; Mayes J; Caudle KE
J Am Pharm Assoc (2003); 2019; 59(5):646-650. PubMed ID: 31327749
[TBL] [Abstract][Full Text] [Related]
16. Perspectives of Pediatric Providers Regarding Clinical Use of Pharmacogenetics.
Avello K; Bell M; Stein Q; Bares V; Landsverk M; Salyakina D; McCafferty-Fernandez J; Kingsmore S; Bedrick A; Bhojwani D; Hoyme HE
S D Med; 2021 Jul; 74(7):294-301. PubMed ID: 34449988
[TBL] [Abstract][Full Text] [Related]
17. Toward Personalized Medicine Implementation: Survey of Military Medicine Providers in the Area of Pharmacogenomics.
DeLuca J; Selig D; Poon L; Livezey J; Oliver T; Barrett J; Turner C; Hellwig L
Mil Med; 2020 Mar; 185(3-4):336-340. PubMed ID: 31786583
[TBL] [Abstract][Full Text] [Related]
18. A clinician's guide for counseling patients on results of a multigene pharmacogenomic panel.
Ho TT; Bell G; Gammal RS; Gregornik D; Wake DT; Dunnenberger HM
Am J Health Syst Pharm; 2022 Sep; 79(19):1634-1644. PubMed ID: 35876085
[TBL] [Abstract][Full Text] [Related]
19. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
Borden BA; Lee SM; Danahey K; Galecki P; Patrick-Miller L; Siegler M; Sorrentino MJ; Sacro Y; Davis AM; Rubin DT; Lipstreuer K; Polonsky TS; Nanda R; Harper WR; Koyner JL; Burnet DL; Stadler WM; Kavitt RT; Meltzer DO; Ratain MJ; O'Donnell PH
Pharmacogenomics J; 2019 Dec; 19(6):528-537. PubMed ID: 30713337
[TBL] [Abstract][Full Text] [Related]
20. Pharmacist's attitudes and knowledge of pharmacogenomics and the factors that may predict future engagement.
Hundertmark ME; Waring SC; Stenehjem DD; Macdonald DA; Sperl DJ; Yapel A; Brown JT
Pharm Pract (Granada); 2020; 18(3):2008. PubMed ID: 32922573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
